Refractory retinal vasoproliferative tumor secondary to congenital toxoplasmosis in a monocular pediatric patient: role of brachytherapy in achieving durable control
Purpose: To report a refractory secondary retinal vasoproliferative tumor (RVPT) associated with congenital toxoplasmosis in a monocular pediatric patient and discuss timing of therapeutic escalation. Methods: Longitudinal follow-up with multimodal imaging in a 13-year-old monocular patient with congenital toxoplasmosis who developed a progressive RVPT unresponsive to sequential therapies, including six intravitreal bevacizumab injections, three intravitreal aflibercept injections, one laser photocoagulation session, and one cryotherapy session. Treatment was escalated to four every-other-week intravitreal faricimab injections and, subsequently, single-session iodine-125 plaque brachytherapy. Results: Every-other-week faricimab produced a significant reduction in tumor activity and exudation, and brachytherapy achieved durable tumor regression; allowing progressive extension of the anti-VEGF and visual acuity preservation (20/25 at presentation, 20/30 at last follow-up). Conclusion: Secondary RVPT associated with congenital toxoplasmosis may be highly treatment-refractory. In cases with progressive activity and risk to central vision, particularly in monocular patients, earlier consideration of brachytherapy may be warranted.
Authors
- Luís Expedito Sabage (ORCID: https://orcid.org/0000-0002-5600-2131)
- Carlos Augusto Moreira Neto (ORCID: https://orcid.org/0000-0001-7370-6395)
- Luiz Fernando Teixeira (ORCID: https://orcid.org/0000-0002-6692-9213)
- Lívia Hastenreiter e Melo Batalha (ORCID: https://orcid.org/0009-0002-2099-1510)
- Gabriel Nogueira Cavalcante
Institutions
- Universidade Sagrado Coração (BR)
- Universidade Positivo (BR)
- Universidade Federal de São Paulo (BR)
Publication Details
- Journal
- Retinal Cases & Brief Reports
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1097/icb.0000000000002015
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00